NUP98 and acute myeloid leukemia: Our findings demonstrate that expression levels of FLT3-ITD and also cell proliferation decrease upon ex vivo revumenib treatment of patient-derived NUP98::NSD1/FLT3-ITD+ AML cells suggesting that the NUP98 fusion is the main driver of leukemia development.22